The dilated cardiomyopathy with ataxia syndrome (DCMA) is an understudied autosomal recessive disease caused by loss-of-function mutations in the poorly characterized gene DNAJC19. Clinically, DCMA is commonly associated with heart failure and early death in affected children through an unknown mechanism.
Introduction
The dilated cardiomyopathy with ataxia syndrome (DCMA) is an autosomal recessive disorder characterized clinically by early-onset cardiac and neurological features (i.e. dilated cardiomyopathy, prolongation of the QT interval, hypotonia, cerebellar ataxia, developmental delay) with 3-methylglutaconic aciduria and other variable systemic features (e.g. abnormal male genitalia, growth failure, microcytic anemia, hepatic steatosis). 1 DCMA is highly prevalent in the Canadian Dariusleut Hutterite population who represent the largest collection of affected individuals in the world. 2 The Hutterites are a religious group, originally immigrating to North America from Europe, that are genetically isolated and share a communal environment. In the Hutterites, DCMA is caused by a single intronic pathogenic variant NG_022933.1:c.130-1G>C (rs137854888) in the DNAJC19 gene resulting in abnormal splicing and a truncated, non-functional protein. 2 DNAJC19 is an inner mitochondrial membrane (IMM) protein and, although some of its interacting partners have been identified, 3 its precise role is unknown and the underlying mechanism by which the DNAJC19 mutation contributes to the DCMA phenotype remains elusive. End-stage heart failure and death in early childhood are common in DCMA patients and, until recently, no effective therapeutic had been identified. 4 Due to the rarity of the disease, randomized clinical drug trials are infeasible and no cellular or animal models have been published to date.
Patient-specific iPSCs have attracted interest for their advantages in elucidating the mechanism underlying rare genetic diseases. [5] [6] [7] [8] Although cell culture models have started to elucidate a role for DNAJC19 as a regulator of IMM structure and function, no one has studied this function in the context of a pathogenic DNAJC19 mutation. 3 Due to the presence of shared biochemical abnormalities and phenotypic overlap, DCMA (3- methylglutaconic aciduria type V) has been grouped together with Barth syndrome (3- methylglutaconic aciduria type II), a rare X-linked disorder that arises from mutations in tafazzin (TAZ) leading to deficiencies in cardiolipin (CL) maturation causing cardiomyopathy (left ventricular dilation or non-compaction), skeletal myopathy, growth retardation and neutropenia. 9 As a key component of mitochondrial membranes, CL has an important role in the proper formation of mitochondrial protein complexes and is disrupted in heart failure. 10 The potential for abnormal mitochondrial structure and function in DCMA due to impaired CL remodeling 3 represents a possible target for therapeutic intervention with the mitochondrially-targeted peptide SS-31 (also known as elamipretide or Bendavia) that interacts specifically with CL to affect membrane curvature, prevent peroxidative damage and maintain mitochondrial structure and integrity. [11] [12] [13] Here, we characterize DCMA-specific iPSCs and the resulting cardiomyocytes generated from two pediatric Hutterite patients with severe cardiac dysfunction. Using these unique and novel cells, we quantified CL composition and mitochondrial structure and evaluated the effect of SS-31. 
Material and Methods

Generation and Characterization of DCMA iPSCs
Reverse Transcription Polymerase Chain Reaction (RT-PCR) and Genomic DNA (gDNA) Sequencing of iPSCs
To confirm the presence of the DNAJC19 mutation, iPSCs were collected for RNA isolation once they reached 70-80% confluency. Total RNA was extracted using the PureLink RNA Mini Kit (ThermoFisher Scientific) according to the manufacturer's protocol followed by DNAse I (ThermoFisher Scientific) digestion. Synthesis of cDNA was performed using RNA (1 µg), Oligo(dT)20 primers (50 µM) and the Superscript IV Reverse Transcriptase kit (ThermoFisher Scientific). PCR amplification was performed in a final volume of 50 μL using Taq DNA Polymerase (ThermoFisher Scientific) and consisted of the following steps: 96°C for 2 min, followed by 35 cycles of 96°C for 30 sec, 56°C for 30 sec, 72°C for 1 min, and 72°C for 7 min. The DNAJC19-specific primers RTF and RTR were designed to amplify a 525 bp cDNA product corresponding to the full-length coding sequence including the 5' and 3' UTR boundaries. The housekeeping gene b-actin was used for normalization. For gDNA sequencing, DNA was extracted from iPSCs using phenol:chloroform (OmniPur). PCR amplification of the DNAJC19 gene was performed in four amplicons: segment 1 (exon 6), segment 2 (exons 4 & 5), segment 3 (exons 1, 2, and 3) and segment 4 (intron 3). All primer sequences are listed in Supplemental Table   S1 . Amplified products were separated on a 1.5% agarose gel, stained with ethidium bromide and then visualized and photographed on a UV transilluminator. All cDNA and gDNA PCR products were sequenced in the DNA Services Laboratory at The University of Calgary.
Differentiation of iPSCs into Cardiomyocytes
Both control and DCMA iPSCs were differentiated into cardiomyocytes based on modifications to a published protocol. 16 Briefly, iPSC colonies were cultured on plates coated with Matrigel (BD Biosciences, cat. BD354277) and cultured in mTeSR1 medium (STEMCELL Technologies, cat. 85875) until they were 80-90% confluent. Differentiation was initiated by changing to RPMI1640 medium containing B-27 (minus insulin) and the glycogen synthase kinase-3 (GSK3) inhibitor CHIR99021 (STEMCELL Technologies, cat. 72052) for 24 h. Cells were exposed to the Wnt signaling inhibitor IWP-4 (STEMCELL Technologies, cat. 72552) for 2 days from days (D) 3 to 5 of differentiation. The cells were then cultured in RPMI1640 medium containing B-27 (minus insulin) for 3 days (D5-D8). A cardiomyocyte purification protocol using L-lactic acid was applied from D8-D12 in glucose-depleted media. 17 Cardiomyocyte clusters were transferred onto gelatin-coated plates containing DMEM/F12 medium supplemented with KnockOut serum replacement (ThermoFisher Scientific, cat. 10828010), GlutaMAX (ThermoFisher Scientific, cat. 35050061) and non-essential amino acids (ThermoFisher Scientific, cat. 11140050) on D12 and maintained in the same media until D20 of differentiation. Media was changed every 3-4 days. Mature iPSC-CMs were collected at either day 20 or 21 of differentiation and were used for all analyses.
Flow Cytometry
To assess the efficiency of our cardiac differentiation protocol, flow cytometry was performed using the cardiac-specific marker troponin T2 (TNNT2). The iPSC-CMs were treated with 0.25% Trypsin-EDTA solution (ThermoFisher Scientific, cat. 25200114) for 5-10 min and then dissociated into single cells. Cells were washed with cardiomyocyte maintenance medium and then centrifuged at 200g for 5 min. Cells were then 
Immunocytochemistry
Following differentiation, immunocytochemistry for TNNT2 and NKX2.5 was performed using the Cardiomyocyte Immunocytochemistry kit (ThermoFisher Scientific, cat. A25973). Nuclei were counterstained using NucBlue and stained cells were imaged using a Zeiss Axiovert microscope with a 20x objective. To visualize the mitochondrial network, iPSC-CMs were stained with TOMM20. Prior to staining, cells were plated as single cells (5 x 10 5 cells) on 35 mm FluoroDish Cell Culture Dishes (World Precision Instruments, cat. WD35-100) and allowed to attach for 72 h. For the SS-31 treated group, cells were incubated with 100 nM SS-31 (d-Arg-2',6'-dimethyltyrosine-Lys-Phe-NH2, synthesized for us by China Peptides) or vehicle control for 24 h. Cells were washed twice with DPBS and then fixed with 4% PFA in DPBS at 37°C for 15 min. Cells were then washed three times with DPBS and quenched with 50 mM NH4Cl for 15 min at RT followed by washing with DPBS. Cells were permeabilized with 0.2% Triton X-100 in DPBS for 15 min followed by blocking with 10% FBS for 25 min at RT. The cells were incubated with TOMM20 primary antibody (Sigma-Aldrich, cat. HPA011562), diluted 1:1000 in 5% fetal bovine serum (FBS), for 1 h at 37°C and then washed three times. Secondary antibody AlexaFluor 488 was diluted 1:1000 in 5% FBS and added to the cells for 1 h at RT. Cells were then washed and stored at 4ºC in the dark until imaged on a Zeiss LSM880 confocal microscope using a 63x oil objective.
Quantification of Mitochondrial Network Fragmentation
Thirty cells from each control and DCMA group were randomly selected and manually graded by a blinded researcher using a published scoring system. 18
Transmission Electron Microscopy (TEM)
To assess mitochondrial ultrastructure, control and DCMA iPSC-CMs were cultured on gelatinized plastic 35 mm cell-culture treated plates (5 x 10 5 cells) for three days. For the SS-31 treated group, cells were incubated with 100 nM SS-31 or vehicle control for 24 h.
Cells were then fixed and imaged using a Hitachi H7650 microscope in The University of Calgary's Microscopy and Imaging Facility. TEM images were exported into FIJI (ImageJ) and 10 mitochondrion were analyzed per group using the "measure perimeter" function.
Western Blotting
We measured the long (L) and short (S) forms of OPA1 using western blotting. All iPSC- 
Cardiolipin Quantification
Mass spectrometry was used to quantify the CL of control and DCMA iPSCs and iPSC-CMs as previously described. 19 Two separate preparations from iPSCs and three separate preparations from iPSC-CMs cultured for 21 days were analyzed.
Statistical Analysis
Data analysis was performed in Prism 8 (GraphPad Software). All data are expressed as mean ± standard deviation (SD) or standard error of the mean (SEM). Significance was determined using a two-way ANOVA with Holm-Sidak multiple-testing correction for the mitochondrial fragmentation data after normalization. A one-way ANOVA was used with Holm-Sidak multiple-testing correction to identify significant differences in mitochondrial perimeter size. A one-way ANOVA was used with Holm-Sidak multiple-testing correction for the OPA1 data after normalization to control. A two-way ANOVA with Holm-Sidak multiple-testing correction was used to compare CL levels between control and each patient sample. A p value < 0.05 was considered significant for all analyses.
Results
Generation of iPSCs and Identification of DNAJC19 Mutation
Control and DCMA iPSCs were generated from PBMCs using non-integrative Sendai virus reprogramming. 14 The iPSCs used in this study came from two Hutterite children from different families (Table 1) harboring the identical homozygous DNAJC19 intronic pathogenic variant NG_022933.1:c.130-1G>C (rs137854888), that appears to be unique to the Hutterite population in southern Alberta. 2 The control iPSC line was derived from a healthy, non-Hutterite individual. The generated iPSCs were characterized using standard pluripotency tests. 20 Immunofluorescence analysis of the iPSCs confirmed positive expression of the human embryonic stem cell (hESC) marker proteins SSEA4 and OCT4 (Supplemental Fig. S1 ).
Through Sanger sequencing of gDNA isolated from the iPSCs, we demonstrated the presence of the G/C transversion at the conserved AG splice acceptor site of intron 3, confirming the presence of the causative DNAJC19 IVS3-1G>C mutation (Fig. 1A) .
Further, to confirm the identity of the cDNA product, we sequenced the 445 bp and 525 bp cDNAs from DCMA and control iPSCs, respectively. As expected, the 445 bp cDNA from the patient iPSCs lacked the coding sequence corresponding to exon 4, while the 525 bp cDNA from control-iPSCs contained the full coding sequence of DNAJC19 (Supplemental Fig. S2 ).
We next confirmed the presence of the DNAJC19 intronic splicing mutation rs137854888 in the patient iPSCs. The iPSCs from both Patient 1 and Patient 2 showed truncated RT-PCR products (445 bp) compared to wild-type hESCs and control-iPSCs (525 bp) ( Fig. 1B) . These results indicate that we successfully established patient-specific DCMA iPSCs that carry the pathogenic DNAJC19 mutation.
Differentiation and Characterization of DCMA iPSC-CMs
To efficiently generate iPSC-CMs for DCMA modeling, we employed a modified monolayer-based myocardial differentiation protocol. 16 Confluent iPSC colonies from both control and patient groups were treated with the GSK3 inhibitor CHIR99021 followed by inhibition of Wnt signaling by IWP-4 (Supplemental Fig. S3 ). Corroborating previously published reports, we found that sequential inhibition of the GSK3 and Wnt signaling pathways stimulated cardiogenesis and caused early formation of cardiac tubes and cardiac mesoderm between days 3-5 of differentiation. 16 Cardiac progenitors and maturation of cardiac tube-like structures were observed on days 5-8 of differentiation.
The first cluster of beating cells was observed on days 7-8 after the induction of differentiation. Following lactate-based metabolic selection, 17 
Cardiolipin Composition
Multiple CL species in iPSCs and iPSC-CMs were quantified using mass spectrometry.
Several small but statistically significant differences were seen between the control and patient iPSCs ( Fig. 2 and Supplemental Table S2 ). Fewer CL species were detectable in the iPSCs compared to the iPSC-CMs (14 vs. 21) and, importantly, the mature form, CL(18:2)4, was not present in significant amounts (<1%) in the iPSCs. In the iPSCs, CL(18:2)(18:1)3 predominanted making up ³40% of the total CL. In the iPSC-CMs, no consistent and significant differences between the DCMA patients and the control strain were seen ( Fig. 3 and Supplemental Table S3 ). There was greater CL diversity in the iPSC-CMs and mature CL contributed between 6.5-14.4% of the total.
Mitochondrial Fragmentation in DCMA iPSC-CMs is Reversible by SS-31
To determine whether the DNAJC19 mutation affected mitochondrial structure in DCMA iPSC-CMs, we stained both control and patient-derived iPSC-CMs for the outer mitochondrial membrane (OMM) marker TOMM20. Qualitatively, mitochondrial networks in DCMA were highly fragmented compared to the control (Fig. 4A ). The mitochondrial networks in DCMA appeared less connected and mitochondria were shorter, whereas control cells showed more fused mitochondrial networks. We then tested whether the mitochondrially-targeted peptide SS-31 could restore mitochondrial morphology and, indeed, the networks in DCMA iPSC-CMs appeared to be less fragmented following SS-31 treatment (Fig. 4A) .
Manual quantification, based on a previously reported grading scale, 18 confirmed our observation of significantly greater fragmentation of the mitochondrial network in both DCMA patients compared to control with a shift towards more fragmented mitochondrial networks in the patient strains ( Fig. 4B-D) . However, in the presence of SS-31, the DCMA iPSC-CMs demonstrated a significant shift towards a less fragmented phenotype (Figs.
4C and 4D). In contrast, SS-31 treatment did not have any significant effect on control iPSC-CMs (Fig. 4A) . The relative frequencies of the fragmentation scale assignments before and after SS-31 are listed in Supplemental Table S4 . These results demonstrate the presence of highly fragmented mitochondria in DCMA-derived iPSC-CMs associated with the DNAJC19 mutation and the reversal of this phenotype by the peptide SS-31.
Reversal of Defects in Mitochondrial Ultrastructure in DCMA iPSC-CMs by SS-31
We next used TEM to evaluate the effects of the DNAJC19 mutation on the mitochondrial ultrastructure of our DCMA iPSC-CMs. Consistent with our observations of mitochondrial network fragmentation, we found abnormally-shaped, swollen mitochondria with disorganized cristae in DCMA compared to elongated mitochondria with well-defined cristae in control (Fig. 5A ). Perimeter length of mitochondria, a measure of mitochondrial size, in the DCMA iPSC-CMs was significantly smaller (p<0.01 for Patient 1 and p<0.05 for Patient 2) compared to control cells (Fig. 5B ). Corroborating the results of our immunocytochemistry, TEM revealed improvements in cristae morphology, mitochondrial shape ( Figure 5A ) and perimeter length (Fig. 5C ) in DCMA iPSC-CMs after SS-31 treatment. These findings indicate that the DNAJC19 mutation is also associated with significant changes in the mitochondrial ultrastructure and that these changes can also be reversed by SS-31.
Modulation of Imbalanced OPA1 by SS-31
The appropriate balance between mitochondrial fusion and fission is one of the hallmarks of mitochondrial health. [22] [23] [24] To assess whether the DNAJC19 mutation affected this balance, we measured the ratio of the long pro-fusion (L-OPA1) and short pro-fission (S-OPA1) isoforms of OPA1, an IMM protein critical for the regulation of mitochondrial fission and fusion. Consistent with the changes in mitochondrial morphology, we found lower levels of L-OPA1 in DCMA iPSC-CMs compared to the control (Fig. 6A) , creating a significantly lower ratio of L-OPA1 / S-OPA1 (p<0.01) (Fig. 6C) . Treatment with SS-31 reduced the processing of OPA1 to the shorter form in DCMA-iPSC-CMs (Fig. 6B) , restoring the isoform ratio back to control levels (Fig. 6D) . These results suggest that the DNAJC19 mutation results in imbalanced OPA1 processing, which interferes with the balance between mitochondrial fusion and fission, resulting in fragmented mitochondria.
Restoration of the appropriate OPA1 isoform balance by SS-31 highlights a potential role for this peptide in affecting the abnormal mitochondrial structure seen in DCMA.
Discussion
In the present study, we describe a novel and unique in vitro model for the mitochondrial disease DCMA created by generating patient-specific iPSCs from two children with genetically-and biochemically-confirmed DCMA and severe cardiac dysfunction, followed by the successful differentiation of these cells into beating iPSC-CMs. We confirmed the presence of the causative DNAJC19 splicing mutation (rs137854888, IVS3-1G>C) in the patient-derived iPSCs which resulted in the loss of the full-length DNAJC19 transcript.
This mutation caused significant mitochondrial fragmentation that was reversible by SS-
31.
Although DCMA is purported to be related to Barth syndrome due to similar abnormalities in metabolism and development, we did not observe consistent, significant changes in CL composition, as has been reported for Barth syndrome. 25, 26 This preliminary observation is of great interest and suggests that the fundamental mechanisms underlying these closely related diseases may be different. However, given the similar phenotypes for DCMA and Barth syndrome, there may exist a cellular relationship between TAZ and DNAJC19 that remains to be elucidated.
DNAJC19 is localized to the IMM but its precise cellular function has not been confirmed in patient-derived cells. Through both confocal microscopy and TEM analyses, we identified highly fragmented mitochondrial networks and ultrastructural defects in DCMA cells confirming that mutated DNAJC19 leads to impaired mitochondrial structure.
In a related observation, we found an imbalance in the isoforms of OPA1 in DCMA iPSC-CMs. The reduction of L-OPA1 relative to S-OPA1 in DCMA supports our hypothesis that the DNAJC19 mutation affects this balance and causes fragmented mitochondria. It has been suggested that DNAJC19 interacts with prohibitin 2 (PHB2). 3 The loss of the PHB complex, as a consequence of decreased DNAJC19, could lead to the activation of IMM proteases and increased processing of L-OPA1. 27 It has previously been shown that imbalanced OPA1 processing and mitochondrial fragmentation are associated with heart failure which is a common clinical phenotype in DCMA. 28 Prior reports have shown that SS-31 interacts specifically with CL to prevent peroxidative damage and maintain mitochondrial structure and integrity. [11] [12] [13] Paralleling results seen in other mitochondrial disorders, 29, 30 the peptide SS-31 showed promise for its ability to reverse the mitochondrial abnormalities found in DCMA. We found reversible mitochondrial fragmentation, improved mitochondrial ultrastructure and restoration of the OPA1 ratio in DCMA iPSC-CMs following exposure to SS-31. Together, these suggest a potential role for SS-31 as a novel therapeutic for the treatment of DCMA. Although SS-31 improved mitochondrial structure and the balance of OPA1 isoforms in our DCMAderived iPSC-CMs, the precise mechanism of its action has not been elucidated in this observational study.
Conclusions
In summary, using a novel in vitro cardiomyocyte model we have described the abnormal mitochondrial structure and ultrastructure in DCMA and identified an imbalance of OPA1 isoforms as a possible mechanism or consequence. We have also demonstrated reversal of this phenotype through treatment with SS-31. Our findings suggest that further evaluation of SS-31 in DCMA is warranted and studies into the mechanism of this poorly understood and heterogeneous disease are now feasible using our patient-derived cells. Supplemental Table S3 . 
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